A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic Dermatitis

• Status: Recruiting
• Trial end date: 2023-09-01
• Target enrollment: 0
• Participant gender: All

Summary

A multicenter, randomized, double-blind, placebo-controlled phase III clinical study of jaktinib hydrochloride tablets in the treatment of adult patients with moderate and severe atopic dermatitis

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Criteria

Inclusion Criteria:

• Have fully understood the test and voluntarily signed the informed consent;

• When signing the informed consent form, the age of male or female subjects must be ≥ 18 years old;

• The onset time of atopic dermatitis was at least 1 year at the time of screening, and the subjects met the Hanifin and Rajka criteria for atopic dermatitis at the time of screening;

• For women with reproductive ability and all male subjects, during the trial period and within 6 months after the discontinuation of the trial drug, they must maintain abstinence or contraception, including but not limited to physical and drug contraception.

• The subjects were able to communicate well and agreed to follow the study and follow-up procedures.

Exclusion Criteria:

• The investigator considers that any subjects are not suitable to participate in the trial.